Tranexamic Acid for the Emergency Treatment of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema.
| Autor: | Hasara S; Department of Pharmacy, Lakeland Regional Health, Lakeland, USA., Wilson K; Department of Pharmacy, Lakeland Regional Health, Lakeland, USA., Amatea J; Department of Emergency Medicine, Lakeland Regional Health, Lakeland, USA., Anderson J; Department of Emergency Medicine, Lakeland Regional Health, Lakeland, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2021 Sep 20; Vol. 13 (9), pp. e18116. Date of Electronic Publication: 2021 Sep 20 (Print Publication: 2021). |
| DOI: | 10.7759/cureus.18116 |
| Abstrakt: | Introduction: Angioedema is a rare but potentially life-threatening adverse effect associated with the use of angiotensin-converting enzyme (ACE) inhibitors. Various therapies, including ecallantide, icatibant, complement-1 esterase inhibitors, and fresh frozen plasma, have been used for treatment with inconsistent results and significant adverse effects. Tranexamic acid (TXA) is used as an alternative for the treatment of hereditary angioedema and it may be an attractive option for the treatment of ACE inhibitor-induced angioedema (ACEi-AE) in the emergency department (ED). The purpose of this study was to evaluate the impact of TXA administration on rates of intubation in patients presenting to the ED with suspected ACEi-AE. Methods: This was an institutional review board-approved, retrospective cohort study conducted at a single-site ED. All patients who received TXA for ACEi-AE in the ED between January 1, 2019 and March 31, 2021 were eligible for inclusion. The primary outcome was the proportion of patients who required intubation for suspected ACEi-AE. Results: A total of 16 patients received TXA in the ED for suspected ACEi-AE during the study timeframe. Of these, two patients were intubated prior to administration of TXA. The remaining 14 patients did not require intubation following TXA administration. Conclusion: Administration of TXA was associated with a low rate of adverse effects and did not contribute to further morbidity when added to standard care in patients presenting to the ED with suspected ACEi-AE. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2021, Hasara et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|